Visipaque is an isosmolar contrast agent developed to further improve the toxicity profile of contrast agents, suitable for patients considered at high risk for cardiovascular or renal insult. Appropriate selection of contrast media for necessary diagnostic or interventional procedure imaging in high-risk patients should be considered to help mitigate the risk of adverse events. Visipaque, an iodinated iso-osmolar, isotonic contrast agent indicated for multiple intra-arterial and intravenous procedures, was prepared with this in mind. Interventional, structural, or endovascular procedures (e.g., TAVI, CTO, PCI) may need to use higher volumes of iodinated CM. Reducing the frequency of adverse reactions has therefore been a driving force in the development of these diagnostic agents since their initial introduction.
Contact Clinical Sales SpecialistWhy surgeons prefer Visipaque™
- The only contrast medium for intravascular use that is isosmolar to blood at all concentrations
- Improved patient care / safety - It is iso-osmolar to blood with the aim of counteracting major fluid shifts across membranes and limiting discomfort.
- Helps reduce costs by helping to reduce risk – lower hospitalisation costs due to shortened length of stay
- Increased patient comfort can help improve throughput - Patient comfort is important in busy interventional radiology suites. Sensation of heat/pain may lead to patient movement, poor image quality and repeat examinations, creating increased radiation and costs
- Role within Oncology – Visipaque can help cancer patients by delivering contrast enhanced diagnostic CT accuracy in patients with renal impairment.
